SILVER SPRING
Enhertu cleared for HER2-positive breast cancer
- Sponsor
- Daiichi Sankyo $DSKYF
- Drug
- Enhertu · fam-trastuzumab deruxtecan-nxki
- Indication
- HER2-positive breast cancer
FDA approved Enhertu for two new indications in HER2-positive breast cancer patients in neoadjuvant and adjuvant settings.
What this means
Enhertu is a breast cancer treatment that combines a HER2-targeting antibody with a cell-killing drug, delivering the payload directly to tumors. FDA expanded its approval to include use before and after surgery for HER2-positive breast cancer patients. This decision gives doctors a new way to attack aggressive tumors earlier in treatment, potentially improving long-term outcomes for more patients.
Drug Watch — recent news on Enhertu
- Complete Response to First-Line Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Extra-axial Central Nervous System Metastases - Cureus
- How Sevabertinib Stacks Up Against Other HER2-Directed NSCLC Options - CancerNetwork
- AstraZeneca LSE:AZN EU Drug Wins Put Cancer and Autoimmune Growth in Focus - kalkinemedia.com
- AstraZeneca and Daiichi Sankyo’s Breast Cancer Drug Approved for NHS Use in England - Yahoo Finance
- AstraZeneca stock gains as Enhertu expands in England - AD HOC NEWS